Illumina made a strategic investment in MyOme and will support a prospective clinical trial that pairs whole‑genome sequencing with MyOme’s AI risk models. MyOme said the Proactive Health trial will evaluate whether WGS plus polygenic/AI risk assessment can improve outcomes and generate healthcare cost savings. The collaboration offers Illumina early access to sequencing capacity and aligns with the company’s multiomics push; MyOme says the approach could enable targeted prevention and reduce downstream healthcare spending. The trial protocol and enrollment plans are being finalized with enrollment expected to start next year. Observers noted the study’s potential to test the real‑world value of population genomics, while flagging operational and payer challenges tied to scaling WGS and demonstrating demonstrable clinical benefit.